In vitro antimicrobial activity of equine platelet lysate and mesenchymal stromal cells against common clinical

Haileigh K Avellar1, John D Lutter1, Charan K Ganta1

  • 1Department of Clinical Sciences (Avellar, Lutter, Beard), Department of Diagnostic Medicine/Pathobiology (Ganta, Smith, Jonnalagadda, Peloquin), College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA; Department of Statistics, College of Arts and Sciences, Kansas State University, Manhattan, Kansas, USA (Kang, Ayub).

Insights

Equine platelet lysate (EPL) and adipose-derived mesenchymal stromal cells (ASCs) showed some ability to inhibit bacterial growth in vitro. While ASCs reduced Staphylococcus aureus growth, results for E. coli were inconclusive, requiring further research.

Area of Science:

  • Veterinary regenerative medicine
  • Antimicrobial therapies
  • Equine medicine

Background:

  • Septic arthritis is a critical condition in horses, leading to severe illness and death.
  • Regenerative therapies like mesenchymal stromal cells and platelet products show antimicrobial potential.
  • Limited research exists on these therapies' efficacy in veterinary species.

Purpose of the Study:

  • To assess the in vitro bacterial suppression capabilities of equine platelet lysate (EPL) and adipose-derived mesenchymal stromal cells (ASCs).
  • To test the hypothesis that both EPL and ASCs inhibit Staphylococcus aureus and Escherichia coli growth.

Main Methods:

  • Equine platelet lysate (EPL) was produced from pooled horse blood.
  • Adipose-derived mesenchymal stromal cells (ASCs) were isolated from equine adipose tissue.
  • In vitro study design compared EPL, ASCs, and a control group against S. aureus and E. coli, measuring bacterial growth over 24 hours.

Main Results:

  • Both S. aureus-ASC and S. aureus-EPL treatments demonstrated decreased bacterial growth.
  • The E. coli-EPL group showed increased bacterial growth, while the E. coli-ASC group showed no significant difference.
  • Results partially supported the hypothesis for S. aureus but not for E. coli.

Conclusions:

  • This in vitro study cannot definitively conclude the antimicrobial effects of EPL and ASCs.
  • ASCs may have a significant effect on reducing Staphylococcus aureus growth.
  • Further research is necessary to explore the antimicrobial potential of these therapies, especially against Gram-positive bacteria.